Cambridge Healthtech Institute’s Second Annual
Overcoming Formulation Challenges for Biopharmaceutical Development
Optimizing Dosage Form and Process Development for New Biotherapeutics
Part of CHI’s 6th Annual The Bioprocessing Summit
August 18-19, 2014 | Renaissance Waterfront Hotel | Boston, Massachusetts
Formulation optimization and process development are the critical steps in developing a protein as a therapeutic product. This popular second annual conference will cover latest trends and challenges in biologic formulations, dosage form optimization, process development and product manufacturing for existing and emerging protein therapeutics. Scientist from around the world will share stories especially unpublished and innovative work, on the use of the effective scale up strategies from R&D to production, process optimization, emerging technologies, and qualification of tools to characterize the quality attributes at different stages of the product lifecycle.
We invite you to join the discussions to learn from and network with the leading experts from around the world.
Novel Molecule Development
Murali Bilikallahalli, Ph.D., Associate Director, Formulation Sciences, Proteins, Vaccines & Oligos, MedImmune
Considerations in Formulation Development of DNA-Based Vaccine
Min Huang, Ph.D., Principal Scientist, Pharmaceutical R&D, Pfizer, Inc.
Aromatic Amino Acid Salts Rescue the Solubility of a Poorly Soluble Multivalent Protein
Yu Tang, Ph.D., Principle Scientist, Integrated Biologics Profiling, Novartis Institute of Biomedical Research
Protein Oxidation during Formulation and Fill Finish Operations
Mark Yang, Ph.D., Director, Fill Finish Development, Commercial Process Development, Genzyme, a Sanofi Company
Talk Title to be Announced
Yuhong Zeng, Ph.D., Senior Scientist, Alcon Laboratories, Inc.
Alternative Methods for Quantifying Temperature- and Formulation-Dependent Aggregation Rates
Christopher J. Roberts, Associate Professor, Dept. of Chemical & Biomolecular Engineering, University of Delaware
The Measurement of KD at Low Concentration and Its Application as a High-Throughput Screening Technique for Protein -Protein Interaction Measurements
Anthony L. Young, Ph.D., Principal Scientist, Pharmaceutical Research and Development, Pfizer, Inc.
Increasing the Throughput of Protein Formulation Screening Using 96-Well Plate Format
Qingyan Hu, Scientist, Ph.D., Scientist, Formulation Development, Regeneron, Inc.
Using High-Throughput Screening Methods to Screen Excipients during Formulation Development
Jamie Biddlecombe, Scientist II, Formulation Sciences, MedImmune UK
Application of DSF as a High-Throughput Tool in Protein Characterization and Formulation Development
Shuai "Sunny" Shi, Ph.D., Senior Scientist, Sterile Product Development, Merck
Breakout Discussions are facilitated, small-group discussions which encourage interactive participation leading to problem-solving and future collaborations around focused topics. Each breakout discussion will be facilitated by a moderator. Attendees can choose to join any topic table they prefer.